Welcome to CDC stacks | The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease - 33433 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease
Filetype[PDF-401.07 KB]


Details:
  • Personal Authors:
  • Keywords:
  • Pubmed ID:
    22374884
  • Pubmed Central ID:
    PMC3448859
  • Description:
    Objective

    The use of psychotropic medications in Alzheimer’s disease (AD) has been associated with both deleterious and potentially beneficial outcomes. We examined the longitudinal association of psychotropic medication use with cognitive, functional, and neuropsychiatric symptom (NPS) trajectories among community-ascertained incident AD cases from the Cache County Dementia Progression Study.

    Methods

    A total of 230 participants were followed for a mean of 3.7 years. Persistency index (PI) was calculated for all antidepressants, selective serotonin reuptake inhibitors (SSRIs), antipsychotics (atypical and typical), and benzodiazepines as the proportion of observed time of medication exposure. Mixed-effects models were used to examine the association between PI for each medication class and Mini-Mental State Exam (MMSE), Clinical Dementia Rating Sum of Boxes (CDR-Sum), and Neuropsychiatric Inventory – Total (NPI-Total) trajectories, controlling for appropriate demographic and clinical covariates.

    Results

    At baseline, psychotropic medication use was associated with greater severity of dementia and poorer medical status. Higher PI for all medication classes was associated with a more rapid decline in MMSE. For antidepressant, SSRI, benzodiazepine, and typical antipsychotic use, a higher PI was associated with a more rapid increase in CDR-Sum. For SSRIs, antipsychotics, and typical antipsychotics, a higher PI was associated with more rapid increase in NPI-Total.

    Conclusions

    Psychotropic medication use was associated with more rapid cognitive and functional decline in AD, and not with improved NPS. Clinicians may tend to prescribe psychotropic medications to AD patients at risk of poorer outcomes, but one cannot rule out the possibility of poorer outcomes being caused by psychotropic medications.

  • Document Type:
    Journal Article
  • Collection(s):
    CDC Public Access
  • Funding:
    09CRP2250944/PHS HHS/United States
    5K08AG029157-03/AG/NIA NIH HHS/United States
    5K12HD043489-08/HD/NICHD NIH HHS/United States
    5R01AG033032-02/AG/NIA NIH HHS/United States
    AG021136/AG/NIA NIH HHS/United States
    AG027841/AG/NIA NIH HHS/United States
    AG028377/AG/NIA NIH HHS/United States
    AG11380/AG/NIA NIH HHS/United States
    E1A6031348/PHS HHS/United States
    K08 AG029157/AG/NIA NIH HHS/United States
    K08 AG029157-01A1/AG/NIA NIH HHS/United States
    P30AAG021334/PHS HHS/United States
    R01 AG 21136/AG/NIA NIH HHS/United States
    R01 AG 31272/AG/NIA NIH HHS/United States
    R01 AG011380/AG/NIA NIH HHS/United States
    R01 AG021136/AG/NIA NIH HHS/United States
    R01 AG031272/AG/NIA NIH HHS/United States
    R01 AG21136/AG/NIA NIH HHS/United States
    R01 MH076953/MH/NIMH NIH HHS/United States
    R01 MH083738/MH/NIMH NIH HHS/United States
    R01 MH085018-01A2/MH/NIMH NIH HHS/United States
    R01 MH087979/MH/NIMH NIH HHS/United States
    R01AG11380/AG/NIA NIH HHS/United States
    R01AG21136/AG/NIA NIH HHS/United States
    R01AG31272/AG/NIA NIH HHS/United States
    R01MH085740-01A2/MH/NIMH NIH HHS/United States
    R01MH086881/MH/NIMH NIH HHS/United States
    R03 AG032427/AG/NIA NIH HHS/United States
    R03AG032427-01A1/AG/NIA NIH HHS/United States
    R15 AG037392/AG/NIA NIH HHS/United States
    R21AG033769/AG/NIA NIH HHS/United States
    R37 AA12303/AA/NIAAA NIH HHS/United States
    R37 DA011796/DA/NIDA NIH HHS/United States
    RAG031348-02S1/PHS HHS/United States
    U01 AG037526/AG/NIA NIH HHS/United States
    U01 DD 000698/DD/NCBDD CDC HHS/United States
    U01 GM092654/GM/NIGMS NIH HHS/United States
    U01 MH066136/MH/NIMH NIH HHS/United States
    U01AG037526-01/AG/NIA NIH HHS/United States
    U01AG15477/AG/NIA NIH HHS/United States
No Related Documents.
You May Also Like:
  1. Effects of General Medical Health on Alzheimer Progression: the Cache County Dementia Progression Study
    Personal Author:
    Leoutsakos, Jeannie-Marie S.; Han, Dingfen; Mielke, Michelle M.; Forrester, Sarah N.; Tschanz, JoAnn T.; Corcoran, Chris D.; Green, Robert C.; Norton, Maria C.; Welsh-Bohmer, Kathleen A.; Lyketsos, Constantine G.;
    Published:
    Jun 12 2012
    Source:
    Int Psychogeriatr. 24(10):1561-1570.
    Description:
    Background : Several observational studies suggested a link between health status and rate of decline among individuals with Alzheimer’s disease (AD). We sought to quantify the relationship in a population-based study of incident AD, and to compare...
    File Type:
    Filetype[PDF - 306.03 KB]
  2. Decreased Basal Ganglia Activation in Subjects with Chronic Fatigue Syndrome: Association with Symptoms of Fatigue
    Personal Author:
    Miller, Andrew H.; Jones, James F.; Drake, Daniel F.; Tian, Hao; Unger, Elizabeth R.; Pagnoni, Giuseppe;
    Published:
    May 23 2014
    Source:
    PLoS One. 2014; 9(5).
    Description:
    Reduced basal ganglia function has been associated with fatigue in neurologic disorders, as well as in patients exposed to chronic immune stimulation. Patients with chronic fatigue syndrome (CFS) have been shown to exhibit symptoms suggestive of decr...
    File Type:
    Filetype[PDF - 1.05 MB]
  3. Cross-lagged panel analysis of depression and behavioral dysfunction in the first year after moderate-to-severe traumatic brain injury
    Personal Author:
    Juengst, Shannon B.; Myrga, John M.; Fann, Jesse R.; Wagner, Amy K.;
    Published:
    Mar 15 2017
    Source:
    J Neuropsychiatry Clin Neurosci. 29(3):260-266.
    Description:
    Timely treatment of depression and behavioral dysfunction after moderate-to-severe traumatic brain injury (TBI) could improve health, function, and quality of life. The authors hypothesized that 6-month depression would be the stronger contributor to...
    File Type:
    Filetype[PDF - 533.88 KB]
  4. Sleep disruption and the sequelae associated with traumatic brain injury
    Personal Author:
    Lucke-Wold, Brandon P.; Smith, Kelly E.; Nguyen, Linda; Turner, Ryan C.; Logsdon, Aric F.; Jackson, Garrett J.; Huber, Jason D.; Rosen, Charles L.; Miller, Diane B.;
    Published:
    May 06 2015
    Source:
    Neurosci Biobehav Rev. 55:68-77.
    Description:
    Sleep disruption, which includes a loss of sleep as well as poor quality fragmented sleep, frequently follows traumatic brain injury (TBI) impacting a large number of patients each year in the United States. Fragmented and/or disrupted sleep can wors...
    File Type:
    Filetype[PDF - 1.35 MB]
  5. Maintenance Treatment of Depression in Old Age: A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Combined with Antidepressant Pharmacotherapy
    Personal Author:
    Reynolds, Charles F.; Butters, Meryl A.; Lopez, Oscar; Pollock, Bruce G.; Dew, Mary Amanda; Mulsant, Benoit H.; Lenze, Eric J.; Holm, Margo; Rogers, Joan C.; Mazumdar, Sati; Houck, Patricia R.; Begley, Amy; Anderson, Stewart; Karp, Jordan F.; Miller, Mark D.; Whyte, Ellen M.; Stack, Jacqueline; Gildengers, Ariel; Szanto, Katalin; Bensasi, Salem; Kaufer, Daniel I.; Kamboh, M. Ilyas; DeKosky, Steven T.;
    Published:
    Jan 2011
    Source:
    Arch Gen Psychiatry. 68(1):51-60.
    Description:
    Context : Cognitive impairment in late-life depression is a core feature of the illness. : Objective : to test whether donepezil + antidepressant is superior to placebo + antidepressant in (1) improving cognitive performance and instrumental activiti...
    File Type:
    Filetype[PDF - 828.42 KB]